Short answer
SUPERNUS PHARMACEUTICALS, INC. (SUPN) filed an 8-K current report with the SEC on November 2, 2026 reporting Item 3.01 (Notice of Delisting). Merger consummated November 2, 2026, ending Supernus common stock trading on Nasdaq.
- This filing includes Item 3.01, an item that often signal trouble.
SUPERNUS PHARMACEUTICALS, INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 3.01 · Notice of Delisting
- Merger consummated November 2, 2026, ending Supernus common stock trading on Nasdaq
- Nasdaq delisting and Section 12(b) deregistration initiated through Form 25
- Planned Form 15 filing would terminate Section 13 and 15(d) SEC reporting obligations
- Shares will no longer trade on any national securities exchange, eliminating public-market liquidity for shareholders
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other SUPERNUS PHARMACEUTICALS, INC. 8-K filings
Get the next SUPN 8-K as it lands
Follow SUPN for push alerts, or ask the research agent what this filing means.